Low-Dose Apixaban Best for Long-Term Use in Cancer

Low-Dose Apixaban Best for Long-Term Use in Cancer

Source: Medscape

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with cancer, and lowered bleeding rates, in API-CAT.

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at least 6 months of anticoagulant treatment after a clot, a… [6899 chars]

Read more